• About
    • About OncoResponse
    • Leadership Team
    • Board of Directors
    • Scientific Advisory Board
    • Investors
  • Science
    • Technology Platform
    • Tumor Microenvironment
    • Publications & Presentations
  • Pipeline
  • Partnering
    • Overview
    • Current Collaborators
  • News Center
    • Press Releases
    • In the News
    • Events & Presentations
  • Contact Us
    • Contact Information
    • Careers

© 2022 OncoResponse      |     SiteMap

OncoResponse Logo OncoResponse Logo
  • About
    • About OncoResponse
    • Leadership Team
    • Board of Directors
    • Scientific Advisory Board
    • Investors
  • Science
    • Technology Platform
    • Tumor Microenvironment
    • Publications & Presentations
  • Pipeline
  • Partnering
    • Overview
    • Current Collaborators
  • News Center
    • Press Releases
    • In the News
    • Events & Presentations
  • Contact Us
    • Contact Information
    • Careers

  • SiteMap

    Header Image
  • About
    • About OncoResponse
    • Leadership Team
    • Board of Directors
    • Scientific Advisory Board
    • Investors
  • Science
    • Technology Platform
    • Tumor Microenvironment
    • Publications & Presentations
  • Pipeline
    • Our Pipeline
  • Partnering
    • Overview
    • Current Collaborators
  • News Center
    • Press Releases
    • In the News
    • Events & Presentations
  • Contact Us
    • Contact Information
    • Careers
    • Privacy Policy
    • FCOI
  • SiteMap
Locations

609 Main St, Suite 4200
Houston, TX 77002 United States

1124 Columbia St, Suite 300
Seattle, WA 98104 United States


info@oncoresponse.com
P: 206-805-1600
F: 206-805-1699

Site Navigation
  • About
  • Science
  • Pipeline
  • Partnering
  • News Center
  • Contact Us
  • Privacy Policy
  • FCOI
News
  • Biotech Strategy Blog: Sally Church's List of Emerging biotechs and novel IO concepts to watch out for November 30, 2022
  • The Bio Report: Learning from “Elite” Responders to Develop Better Immunotherapies October 27, 2022
  • Scientific Inquirer: Industry Matters: From Elite Responders to M2 macrophages – OncoResponse’s approach to cancer immunotherapy August 31, 2022
  •     

© 2025 OncoResponse

SiteMap
Top
OncoResponse Logo